Plasma-derived human antithrombin attenuates ventilator-induced coagulopathy but not inflammation in a Streptococcus pneumoniae pneumonia model in rats

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 3, 2012, Pages 399-410

  Aslami, H ^a,b   Haitsma, J J ^a   Hofstra, J J ^b   Florquin, S ^b   Dos Santos, C ^a   Streutker, C ^c   Zhang, H ^a   Levi, M ^b   Slutsky, A S ^a   Schultz, M J ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antithrombin; Coagulopathy; Inflammation; Pneumonia; Ventilator induced lung injury

Indexed keywords

ANTITHROMBIN; FIBRIN DEGRADATION PRODUCT; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; INFLAMMATION; LUNG LAVAGE; MALE; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RAT; STREPTOCOCCUS PNEUMONIA; TIDAL VOLUME; VENTILATOR INDUCED COAGULOPATHY;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN PROTEINS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; LUNG; MALE; PNEUMONIA, PNEUMOCOCCAL; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATION, ARTIFICIAL; TIME FACTORS; VENTILATOR-INDUCED LUNG INJURY;

EID: 84863248517     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04622.x     Document Type: Article

References (56)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
2. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006; 34: 871-7.
3. Choi G, Wolthuis EK, Bresser P, Levi M, van der Poll T, Dzoljic M, Vroom MB, Schultz MJ. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 2006; 105: 689-95.
4. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
5. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44.
6. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-23.
7. Kipnis E, Guery BP, Tournoys A, Leroy X, Robriquet L, Fialdes P, Neviere R, Fourrier F. Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004; 21: 444-51.
8. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-10.
9. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
10. Petty JM, Sueblinvong V, Lenox CC, Jones CC, Cosgrove GP, Cool CD, Rai PR, Brown KK, Weiss DJ, Poynter ME, Suratt BT. Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J Immunol 2007; 178: 8148-57.
11. Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost 2003; 90: 1150-7.
12. Choi G, Schultz MJ, Levi M, van der Poll T, Millo JL, Garrard CS. Protein C in pneumonia. Thorax 2005; 60: 705-6.
13. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G III, Bernard GR. Effects of drotrecogin alfa activated on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31: 834-40.
14. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952-61.
15. Laterre PF. Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care 2008; 12(Suppl 6): S4.
16. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24: 663-72.
17. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
18. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, van der Zee JS, Florquin S, van der PT, Levi M, Schultz MJ. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36: 204-10.
19. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, Schultz MJ. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 2009; 13: R145.
20. Brochard L, Roudot-Thoraval F, Roupie E, Delclaux C, Chastre J, Fernandez-Mondejar E, Clementi E, Mancebo J, Factor P, Matamis D, Ranieri M, Blanch L, Rodi G, Mentec H, Dreyfuss D, Ferrer M, Brun-Buisson C, Tobin M, Lemaire F. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The multicenter trail group on tidal volume reduction in ARDS. Am J Respir Crit Care Med 1998; 158: 1831-8.
21. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338: 347-54.
22. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000; 342: 1301-8.
23. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, Rana R, St SJ, Lymp JF, Afessa B, Hubmayr RD. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004; 32: 1817-24.
24. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A. Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med 2005; 31: 922-6.
25. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Wolthuis EK, Meijers JC, Lachmann B. Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J 2006; 28: 992-8.
26. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Meijers JC, Lachmann B. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 2005; 31: 724-32.
27. Haitsma JJ, Schultz MJ, Hofstra JJ, Kuiper JW, Juco J, Vaschetto R, Levi M, Zhang H, Slutsky AS. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Eur Respir J 2008; 32: 1599-606.
28. Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, van Gulik TM. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004; 32: 1375-83.
29. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 2008; 34: 361-7.
30. Verheijen JH, Mullaart E, Chang GT, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic tissue-type plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-9.
31. Peters M, Breederveld C, Kahle LH, ten Cate JW. Rapid microanalysis of coagulation parameters by automated chromogenic substrated methods - application in neonatal patients. Thromb Res 1982; 28: 773-81.
32. Haitsma JJ, Uhlig S, Verbrugge SJ, Goggel R, Poelma DL, Lachmann B. Injurious ventilation strategies cause systemic release of IL-6 and MIP-2 in rats in vivo. Clin Physiol Funct Imaging 2003; 23: 349-53.
33. Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, Lijnen HR, Weening JJ, Florquin S. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-40.
34. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
35. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 474: 305-14.
36. Choi G, Schultz MJ, Levi M, van der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly 2006; 136: 139-44.
37. Schouten M, van't veer C, Roelofs JJ, Gerlitz B, Grinnell BW, Levi M, van der Poll T. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb Haemost 2011; 106: 1189-96.
38. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. Polymorphonuclear leukocyte transit times in bone marrow during streptococcal pneumonia. Am J Physiol 1996; 271: L587-92.
39. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35: 1821-8.
40. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22: 401-4.
41. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
42. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR et al. Efficacy and safety of tifacogin recombinant tissue factor pathway inhibitor in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
43. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171: 1125-8.
44. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-202.
45. Maniatis NA, Letsiou E, Orfanos SE, Kardara M, Dimopoulou I, Nakos G, Lekka ME, Roussos C, Armaganidis A, Kotanidou A. Inhaled activated protein C protects mice from ventilator-induced lung injury. Crit Care 2010; 14: R70.
46. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178: 618-23.
47. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995; 34: 5725-35.
48. Streusand VJ, Bjork I, Gettins PG, Petitou M, Olson ST. Mechanism of acceleration of antithrombin-proteinase reactions by low affinity heparin. Role of the antithrombin binding pentasaccharide in heparin rate enhancement. J Biol Chem 1995; 270: 9043-51.
49. Jiang JS, Chou HC, Wang LF, Lang YD, Chen CM. Effects of activated protein C on ventilator-induced lung injury in rats. Respiration 2010; 80: 246-53.
50. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, Damas P, Armaganidis A, Lemaire F. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004; 30: 51-61.
51. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
52. Metnitz PG, Metnitz B, Moreno RP, Bauer P, Del SL, Hoermann C, de Carvalho SA, Ranieri VM. Epidemiology of mechanical ventilation: analysis of the SAPS 3 database. Intensive Care Med 2009; 35: 816-25.
53. Weber-Carstens S, Bercker S, Hommel M, Deja M, MacGuill M, Dreykluft C, Kaisers U. Hypercapnia in late-phase ALI/ARDS: providing spontaneous breathing using pumpless extracorporeal lung assist. Intensive Care Med 2009; 35: 1100-5.
54. Peek GJ, Moore HM, Moore N, Sosnowski AW, Firmin RK. Extracorporeal membrane oxygenation for adult respiratory failure. Chest 1997; 112: 759-64.
55. Schultz MJ, Haitsma JJ, Slutsky AS, Gajic O. What tidal volumes should be used in patients without acute lung injury? Anesthesiology 2007; 106: 1226-31.
56. Ylipalosaari P, Ala-Kokko TI, Laurila J, Ohtonen P, Syrjala H. Community- and hospital-acquired infections necessitating ICU admission: spectrum, co-morbidities and outcome. J Infect 2006; 53: 85-92.